substance P (6-11), pGlu(6)-: pyroglutamic acid deriv of the C-terminal of Substance P [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 188348 |
| CHEMBL ID | 441061 |
| MeSH ID | M0086415 |
| Synonym |
|---|
| 61123-13-5 |
| CHEMBL441061 , |
| 6-pglu-substance p (6-11) |
| substance p (6-11), pglu(6)- |
| l-methioninamide, 5-oxo-l-prolyl-l-phenylalanyl-l-phenylalanylglycyl-l-leucyl- |
| 6-pglu-sp(6-11) |
| substance p, c-terminal pentapeptide |
| 5-oxo-pro-phe-phe-gly-leu-met-amide |
| substance p (6-11), pyroglutamic acid- |
| e-sp(7-11) |
| substance p (6-11), hexapeptide-pglu(6)- |
| pglu6-phe-phe-gly-leu-met-nh2 |
| bdbm50007963 |
| (2s)-n-[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-5-oxopyrrolidine-2-carboxamide |
| pglu-phe-phe-gly-leu-met-nh2 |
| glp-phe-phe-gly-leu-met-nh2 |
| (s)-n-((5s,8s,14s,17s)-14-benzyl-5-carbamoyl-8-isobutyl-7,10,13,16-tetraoxo-18-phenyl-2-thia-6,9,12,15-tetraazaoctadecan-17-yl)-5-oxopyrrolidine-2-carboxamide |
| n-{14-benzyl-7,10,13,16-tetrahydroxy-5-[hydroxy(imino)methyl]-8-(2-methylpropyl)-18-phenyl-2-thia-6,9,12,15-tetraazaoctadeca-6,9,12,15-tetraen-17-yl}-5-hydroxy-3,4-dihydro-2h-pyrrole-2-carboximidic acid |
| DTXSID50976640 |
| CS-0621309 |
| [glp6] substance p (6-11) |
| HY-P3799 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID144420 | Effective dose was measured on NK1 receptors of guinea pig ileum for maximal contraction in the presence of 3*10e-7 M atropine | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Pseudopeptide analogues of substance P and leucine enkephalinamide containing the psi (CH2O) modification: synthesis and biological activity. |
| AID175878 | Inhibitory effect was measured on electrically stimulated rat vas deferens contraction | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Pseudopeptide analogues of substance P and leucine enkephalinamide containing the psi (CH2O) modification: synthesis and biological activity. |
| AID78838 | Effective dose was measured on guinea pig ileum for maximal contraction | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Pseudopeptide analogues of substance P and leucine enkephalinamide containing the psi (CH2O) modification: synthesis and biological activity. |
| AID230245 | Ratio of NK-1 receptor to that of NK-3 receptor | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Pseudopeptide analogues of substance P and leucine enkephalinamide containing the psi (CH2O) modification: synthesis and biological activity. |
| AID144550 | Effective dose was measured on NK3 receptors of guinea pig ileum for maximal contraction in the presence of 10e-7 M substance P methyl ester | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Pseudopeptide analogues of substance P and leucine enkephalinamide containing the psi (CH2O) modification: synthesis and biological activity. |
| AID79360 | Relative potency as ratio of the EC50 value of analogue to that of [PGlu6]SP6-11 in tachykinin receptor 3 in guinea pig ileum | 1991 | Journal of medicinal chemistry, Aug, Volume: 34, Issue:8 | Pseudopeptide analogues of substance P and leucine enkephalinamide containing the psi (CH2O) modification: synthesis and biological activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 10 (76.92) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||